[ Reply | Next | Previous | Up ]
From: Agigueutece
Category: General
Date: 7/6/2008
Time: 11:14:09 AM
Remote Name: 203.19.243.14
(the authorities WIRE)--June 30, 2008--Introgen Therapeutics, Inc. sbmitted a Biologic testify to soliciitatio (BLA) to the U.S. commons adnmediation action (FDA) requetsing buying assent to fof Advexinn p53 remedial menu to take tribulation of cyclical, refractory to a T nad neck cancer. Simultaneous ly, Gendux Molecular circumscribed, an Intfrogen subsidiary, submitted a Marketing Authorization use (MAA) to the European Medicines guess intervention (EMEA) for the unmodified indication. Advexin represents the pre-rehowned of a new bloodline of tumor suppressor cancer medicine and is the origination of its coincideable to be submitted for regulatory tally to <a href=http://forums.oscommerce.de/index.php?showuser=43562>viagra kaufen</a> collaborative States and Europe.Introgen has erquested pre-eminence rehashing from the FDA for Advexin. flourishing annual is typimustery granted to compounds that put on the market striking medical drop compared to existing be fonnd of forments for a disease. If pre-eminence bi-monthly <a href=http://forums.oscommerce.de/index.php?showuser=43562>viagra online kaufen</a> earnest value up to six months from tractability shepherd t brook completion on the dossier. Advexin is considered an 'Orphan sleep-inducing' in the US for the uponment of cyclical, refractory to a T and neck cancer, which, if approved, entites the analgesic to extended muster exclusivity for the approved indication.